Initial results from a first-in-human, phase I study of immunomodulatory aryl hydrocarbon receptor (AhR) inhibitor BAY2416964 in patients with advanced solid tumors

被引：0
|
作者：
Dumbrava, Ecaterina Elena
Cecchini, Michael
Zugazagoitia, Jon
Lopez, Juanita Suzanne
Jager, Dirk
Oliva, Marc
Ochsenreither, Sebastian
Gambardella, Valentina
Chung, Ki Y.
Longo, Federico
Razak, Albiruni Ryan Abdul
Wermke, Martin
Evans, T. R. Jeffry
Cook, Natalie
Chenard-Poirier, Maxime
Pencheva, Radost
Schaer, David
Wagener, Thomas
Wagner, Andrea
Papadopoulos, Kyriakos P.
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX USA
[2] Yale Univ, Sch Med, New Haven, CT USA
[3] Hosp Univ 12 Octubre, Madrid, Spain
[4] Royal Marsden NHS Trust, Sutton, Surrey, England
[5] NCT Heidelberg, Heidelberg, Germany
[6] Lhosp & Inst Invest Biomed Bellvitge IDIBELL, ICO, Barcelona, Spain
[7] Charite Univ Med Berlin, Berlin, Germany
[8] INCLIVA Biomed Res Inst, Valencia, Spain
[9] Prisma Hlth Canc Inst, Greenville, SC USA
[10] Hosp Univ Ramo y Cajal, Madrid, Spain
[11] Princess Margaret Canc Ctr, Toronto, ON, Canada
[12] Tech Univ Dresden, Fac Med, NCT UCC Early Clin Trial Unit, Dresden, Germany
[13] Univ Glasgow, Glasgow, Lanark, Scotland
[14] Christie Hosp NHS Fdn Trust, Manchester, Lancs, England
[15] Univ Manchester, Manchester, Lancs, England
[16] Univ Laval, CHU Quebec, Quebec City, PQ, Canada
[17] Bayer PLC, Reading, Berks, England
[18] Bayer Healthcare Pharmaceut Inc, Whippany, NJ USA
[19] Bayer AG, Berlin, Germany
[20] START San Antonio, San Antonio, TX USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2502
引用
收藏
页数：1
相关论文
共 50 条
  • [21] First-in-Human Phase I Study of an Oral HSP90 Inhibitor, TAS-116, in Patients with Advanced Solid Tumors
    Shimomura, Akihiko
    Yamamoto, Noboru
    Kondol, Shunsuke
    Fujiwara, Yutaka
    Suzuki, Shigenobu
    Yanagitani, Noriko
    Horiike, Atsushi
    Kitazono, Satoru
    Ohyanagi, Fumiyoshi
    Doi, Toshihiko
    Kuboki, Yasutoshi
    Kawazoe, Akihito
    Shitara, Kohei
    Ohno, Izumi
    Banerji, Udai
    Sundar, Raghav
    Ohkubo, Shuichi
    Calleja, Elizabeth M.
    Nishio, Makoto
    MOLECULAR CANCER THERAPEUTICS, 2019, 18 (03) : 531 - 540
  • [22] First-in-human, phase I study of KC1036, a multiple kinase inhibitor, as a single agent in patients with advanced solid tumors
    Li, Xiaoyu
    Shen, Qi
    Shu, Pei
    Qin, Diyuan
    Tang, Jie
    Zheng, Li
    Li, Qiu
    Gong, Yi
    Hao, Xinbao
    Wang, Yongsheng
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [23] A first-in-human phase I study of ATR inhibitor M1774 in patients with solid tumors.
    Yap, Timothy A.
    Tolcher, Anthony W.
    Plummer, Elizabeth Ruth
    Becker, Andreas
    Fleuranceau-Morel, Patricia
    Goddemeier, Thomas
    Locatelli, Giuseppe
    Gounaris, Ioannis
    De Bono, Johann S.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [24] A Phase I First-in-Human Trial of Bardoxolone Methyl in Patients with Advanced Solid Tumors and Lymphomas
    Hong, David S.
    Kurzrock, Razelle
    Supko, Jeffrey G.
    He, Xiaoying
    Naing, Aung
    Wheler, Jennifer
    Lawrence, Donald
    Eder, Joseph Paul
    Meyer, Colin J.
    Ferguson, Deborah A.
    Mier, James
    Konopleva, Marina
    Konoplev, Sergej
    Andreeff, Michael
    Kufe, Donald
    Lazarus, Hillard
    Shapiro, Geoffrey I.
    Dezube, Bruce J.
    CLINICAL CANCER RESEARCH, 2012, 18 (12) : 3396 - 3406
  • [25] THE EVOLUTION OF PI3 KINASE INHIBITORS: RESULTS OF A FIRST-IN-HUMAN PHASE I STUDY OF BAY80-6946 IN ADVANCED SOLID TUMORS
    Patnaik, A.
    Ramanathan, R. K.
    Dubowy, R.
    Tolcher, A. W.
    Papadopoulos, K. P.
    Beeram, M.
    Mountz, J. M.
    Rasco, D.
    Lotze, M. T.
    Laymon, C.
    Rajagopalan, P.
    Carrizales, G.
    Rankin, N.
    Hull, L.
    Jeffers, M.
    Roth, D.
    Appleman, L. J.
    ANNALS OF ONCOLOGY, 2012, 23 : 16 - 16
  • [26] A phase I first-in-human study of PRI-724 in patients (pts) with advanced solid tumors.
    El-Khoueiry, Anthony B.
    Ning, Yan
    Yang, Dongyun
    Cole, Sarah
    Kahn, Michael
    Zoghbi, Marwan
    Berg, Jennifer
    Fujimori, Masamoto
    Inada, Tetsuhi
    Kouji, Hiroyuki
    Lenz, Heinz-Josef
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [27] First-in-human phase I dose escalation study of MK-8033 in patients with advanced solid tumors
    Keedy, Vicki L.
    Lenz, Heinz-Josef
    Saltz, Leonard
    Whisenant, Jennifer G.
    Berlin, Jordan D.
    Camacho, Luis H.
    INVESTIGATIONAL NEW DRUGS, 2018, 36 (05) : 860 - 868
  • [28] First-in-human phase I dose escalation study of MK-8033 in patients with advanced solid tumors
    Vicki L. Keedy
    Heinz-Josef Lenz
    Leonard Saltz
    Jennifer G. Whisenant
    Jordan D. Berlin
    Luis H. Camacho
    Investigational New Drugs, 2018, 36 : 860 - 868
  • [29] A first-in-human phase I study of MORAb-202 in patients with folate receptor alpha-positive advanced solid tumors
    Sato, J.
    Shimizu, T.
    Fujiwara, Y.
    Yonemori, K.
    Koyama, T.
    Shimomura, A.
    Tamura, K.
    Iwasa, S.
    Kondo, S.
    Sudo, K.
    Ikezawa, H.
    Nomoto, M.
    Nakajima, R.
    Miura, T.
    Yamamoto, N.
    ANNALS OF ONCOLOGY, 2020, 31 : S5 - S6
  • [30] Results from the first-in-human study of ATR inhibitor, IMP9064 monotherapy dose escalation in patients with advanced solid tumors
    Lin, C-C.
    Schneider, R.
    Gutierrez, M.
    Shen, L.
    Chung, K.
    Doroshow, D. B.
    Gao, B.
    Millward, M.
    Hsieh, C-Y.
    Xu, C.
    Cai, S. X.
    Tian, Y. E.
    Liu, L.
    Shen, C.
    Tan, Y.
    He, Y.
    Zhang, C.
    Li, L.
    Ma, M.
    Xu, L.
    ANNALS OF ONCOLOGY, 2024, 35 : S503 - S504
12345